Action SPRY ARS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Temps réel estimé Cboe BZX
Autres places de cotation
 18:20:00 11/06/2024 		Varia. 5j. Varia. 1 janv.
8,99 USD -0,88 % Graphique intraday de ARS Pharmaceuticals, Inc. +0,34 % +63,69 %
09/05 ARS Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
30/04 ARS Pharmaceuticals, Inc. soumet au CHMP de l'EMA sa réponse à la demande d'autorisation de mise sur le marché de Neffy (spray nasal à l'épinéphrine) CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
North American Morning Briefing : Stock Futures -2-
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SPRY
  4. Actualités ARS Pharmaceuticals, Inc.
  5. Autres langues